Related Experiment Video
Updated: Jun 18, 2025
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Cardiogenic Shock: Focus on Non-Cardiac Biomarkers
Hadi Beaini1, Zainali Chunawala1,2, Daniel Cheeran1,3
1Department of Medicine, The University of Texas Southwestern Medical Center, 5959 Harry Hines Blvd, Dallas, TX, 75235, USA.
Insights
Non-cardiac biomarkers like lactate and glucose offer new insights into cardiogenic shock (CS) management. These markers improve diagnosis and prognosis, guiding better patient care for this critical condition.
Area of Science:
- Cardiology
- Biomarker Research
- Critical Care Medicine
Background:
- Cardiogenic shock (CS) is a complex condition with high mortality.
- Standard assessments focus on cardiac structure and function.
- There is a need for improved risk stratification and management strategies in CS.
Purpose of the Study:
- To explore the role of non-cardiac biomarkers in understanding and managing cardiogenic shock (CS).
- To assess how these biomarkers enhance diagnostic accuracy and prognostic evaluation in CS patients.
Main Methods:
- Review of current literature on non-cardiac biomarkers in cardiogenic shock.
- Analysis of data concerning lactate, glucose, and inflammation markers.
- Evaluation of insights provided by biomarkers beyond traditional cardiac assessments.
Main Results:
- Increasing evidence supports the utility of lactate, glucose, and inflammation markers in CS.
- These biomarkers offer a deeper understanding of hemo-metabolic and cellular disturbances.
- Non-cardiac biomarkers refine diagnosis and improve prognostic accuracy in CS.
Conclusions:
- Non-cardiac biomarkers provide valuable insights into cardiogenic shock.
- They enhance diagnostic and prognostic capabilities, aiding clinical decision-making.
- Further research into novel biomarkers is crucial for targeted therapies in CS.
Purpose Of Review:
To examine the evolving multifaceted nature of cardiogenic shock (CS) in the context of non-cardiac biomarkers that may improve CS management and risk stratification.
Recent Findings:
There are increasing data highlighting the role of lactate, glucose, and other markers of inflammation and end-organ dysfunction in CS. These biomarkers provide a more comprehensive understanding of the concurrent hemo-metabolic and cellular disturbances observed in CS and offer insights beyond standard structural and functional cardiac assessments. Non-cardiac biomarkers both refine the diagnostic accuracy and improve the prognostic assessments in CS. Further studies revolving around novel biomarkers are warranted to support more targeted and effective therapeutic and management interventions in these high-risk patients.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:24Blood Pressure Imbalances and Circulatory Shock
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System